Overview
- Health authorities report more than 10,000 confirmed Ebola infections and over 5,000 deaths in the Democratic Republic of Congo, making this the country's largest documented Ebola epidemic.
- The Tumaini adaptive vaccine trial began on 23 October and has started ring vaccinations with several tens of thousands of doses of the licensed Ervebo vaccine to protect contacts of cases and gather early effectiveness data.
- A German laboratory study found that T cells from people vaccinated with Ervebo recognize the Bundibugyo virus, a finding that suggests possible cross‑reactive immunity but does not prove clinical protection.
- Two Bundibugyo‑specific vaccine candidates from the University of Oxford and Moderna are in phase‑1 human testing and could be added to Tumaini after their safety is demonstrated.
- Response and research are constrained by armed groups, attacks on clinics, long sample transport routes, limited diagnostics and incomplete contact tracing, which worsen surveillance, delay care and strain routine health services.